GRANULES INDIA LTD.-$ - 532482 - Clarifies on News item
With reference to news appeared in moneycontrol.com dated September 25, 2020 quoting "Granules India shares hit 52-week high as global equity firms eye controlling stake", Granules India Ltd has submitted to BSE a copy of Clarification is enclosed. GRANULES INDIA LTD.-$ - 532482 - Clarification sought from Granules India Ltd
The Exchange has sought clarification from Granules India Ltd on September 25, 2020, with reference to news appeared in moneycontrol.com dated September 25, 2020 quoting "Granules India shares hit 52-week high as global equity firms eye controlling stake".The reply is awaited. GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited announces US FDA approval of Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC) GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Grant of Stock Options. GRANULES INDIA LTD.-$ - 532482 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for FMR LLC & FIL Ltd
Buy Granules India; target of Rs 410: Motilal Oswal
Motilal Oswal is bullish on Granules India recommended buy rating on the stock with a target price of Rs 410 in its research report dated September 12, 2020.
Granules India gains 5% on US FDA approval for ADHD drug
The drug will be manufactured at the Granules manufacturing facility in Chantilly, Virginia. The company now has a total of 30 ANDA approvals from the USFDA, of which 28 are final approvals and 2 are tentative. GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules Receives USFDA approval for complex, Attention Deficit Hyperactivity Disorder (ADHD) Drug Granules India hits fresh record high of Rs 384; rallies 24% in 2 weeks
Analysts expect launches in formulations and additional capacity in pharmaceutical formulation intermediate (PFIs) to be key growth drivers GRANULES INDIA LTD.-$ - 532482 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd